Abstract
Background
Acute osteomyelitis still represents a significant clinical challenge, with an increasing incidence in paediatric population. A careful assessment and a rapid diagnosis with proper timing and choice of empirical antimicrobial therapy are necessary to avoid sequelae. The initial treatment should consist of empirical antibiotic therapy, to cover the major responsible pathogens in each age group.
Data sources
We made a literature search with PubMed and Cochrane database from 2000 to 2019 in English, French, and Spanish languages using the key words “osteomyelitis, children, clinical, diagnosis, and treatment”.
Results
The child’s clinical features, age, and the microbiological profile of the geographic area should be evaluated for diagnosis and in the choice of antibiotic treatment. Latest data suggest the administration of intravenous antibiotics for a short period, with subsequent oral therapy, according to the improvement of clinical status and inflammatory markers. For children older than 3 months, the shift to oral medications is already possible after a short course of intravenous therapy, until recovery. The timing for the shift from cefazolin to cephalexin or cefuroxime, intravenous clindamycin to oral clindamycin, and intravenous ceftriaxone + oxacillin to oral equivalents will be decided according to the improvement of clinical status and inflammatory markers. We also present the approach to osteomyelitis due to difficult pathogens, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Panton-Valentine leukocidin (PVL)-positive S. aureus infections.
Conclusion
In this review, we present the current approach to the clinical diagnosis and management of osteomyelitis in childhood, with an update on recent recommendations, as a useful instrument to understand the rationale of antibiotic therapy.
Similar content being viewed by others
References
Whyte NSB, Bielski RJ. Acute hematogenous osteomyelitis in children. Pediatr Ann. 2016;45:e204–8.
Davis WT, Gilbert SR. Comparison of methicillin-resistant versus susceptible staphylococcus aureus pediatric osteomyelitis. J Pediatr Orthop. 2018;38:e285–91.
Hamdy RF, Dona D, Jacobs MB, Gerber JS. Risk factors for complications in children with Staphylococcus aureus bacteremia. J Pediatr. 2019;208:214–220.e2.
Arnold JC, Bradley JS. Osteoarticular infections in children. Infect Dis Clin North Am. 2015;29:557–74.
Yeo A, Ramachandran M. Acute haematogenous osteomyelitis in children. BMJ. 2014;348:g66.
Paakkonen M, Peltola H. Acute osteomyelitis in children. N Engl J Med. 2014;370:1365–6.
Howard-Jones AR, Isaacs D. Systematic review of duration and choice of systemic antibiotic therapy for acute haematogenous bacterial osteomyelitis in children. J Paediatr Child Health. 2013;49:760–8.
Dartnell J, Ramachandran M, Katchburian M. Haematogenous acute and subacute paediatric osteomyelitis. J Bone Jt Surg Br. 2012;94B:584–95.
Boccuzzi E, Buonsenso D, Ferro V, Raucci U, Reale A, Piga S, et al. The osteoarticular infection in a pediatric emergencysetting: a challenging diagnosis. Pediatr Emerg Care. 2020;36:e108–14.
Batchelder N, So TY. Transitioning antimicrobials from intravenous to oral in pediatric acute uncomplicated osteomyelitis. World J Clin Pediatr. 2016;5:244–50.
Thomsen I, Creech CB. Advances in the diagnosis and management of pediatric osteomyelitis. Curr Infect Dis Rep. 2011;13:451–60.
Ju KL, Zurakowski D, Kocher MS. Differentiating between methicillin-resistant and methicillin-sensitive Staphylococcus aureus osteomyelitis in children: an evidence-based clinical prediction algorithm. J Bone Jt Surg Am. 2011;93:1693–701.
Paakkonen M, Kallio MJT, Kallio PE, Peltola H. Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections. Clin Orthop Relat Res. 2010;468:861–6.
Jaramillo D, Dormans JP, Delgado J, Laor T, St Geme JW. Hematogenous osteomyelitis in Infants and children: imaging of a changing disease. Radiology. 2017;283:629–43.
Schweitzer A, Della Beffa C, Akmatov MK, Narchi H, Abaev YK, Sherry DD, et al. Primary osteomyelitis of the sternum in the pediatric age group: report of a new case and comprehensive analysis of seventy-four cases. Pediatr Infect Dis J. 2015;34:e92–101.
Mellado Santos JM. Diagnostic imaging of pediatric hematogenous osteomyelitis: lessons learned from a multi-modality approach. Eur Radiol. 2006;16:2109–19.
Colston J, Atkins B. Bone and joint infection. Clin Med J R Coll Physicians Lond. 2018;18:150–4.
Arnold JC, Cannavino CR, Ross MK, Westley B, Miller TC, Riffenburgh RH, et al. Acute bacterial osteoarticular infections: eight-year analysis of C-reactive protein for oral step-down therapy. Pediatrics. 2012;130:e821–8.
Montgomery NI, Rosenfeld S. Pediatric osteoarticular infection update. J Pediatr Orthop. 2015;35:74–81.
Hoppe P-A, Holzhauer S, Lala B, Bührer C, Gratopp A, Hanitsch LG, et al. Severe infections of Panton-Valentine leukocidin positive Staphylococcus aureus in children. Med (Baltim). 2019;98:e17185.
Hardy C, Osei L, Basset T, Elenga N. Bone and joint infections with Staphylococcus aureus strains producing Panton–Valentine leukocidin in French Guiana. Med (Baltim). 2019;98:e16015.
Sankar R. Bone and joint infections in children. Indian J Pract Pediatr. 2015;17:301–7.
Yagupsky P, Porsch E, 3rd St Geme JW. Kingella kingae: an emerging pathogen in young children. Pediatrics. 2011;127:557–65.
Saphyakhajon P. Empiric antibiotic therapy for acute osteoarticular infections with suspected methicillin-resistant staphylococcus aureus or kingella. Pediatr Infect Dis J. 2008;27:765–7.
Chambers JB, Forsythe DA, Bertrand SL, Iwinski HJ, Steflik DE. Retrospective review of osteoarticular infections in a pediatric sickle cell age group. J Pediatr Orthop. 2000;20:682–5.
Miller LJ, Meier Riehm E. Sickle cell disease in children. Drugs. 2012;72:895–906.
Piehl FC, Davis RJ, Prugh SI. Osteomyelitis in sickle cell disease. J Pediatr Orthop. 1993;13:225–7.
Song KM, Sloboda JF. Acute hematogenous osteomyelitis in children. J Am Acad Orthop Surg. 2001;9:166–75.
Donà D, Fovino LN, Mozzo E, Cabrelle G, Bordin G, Lundin R, et al. Case report osteomyelitis in cat-scratch disease : a never-ending dilemma — a case report and literature review. Case Rep Pediatr. 2018;8:1679306.
Peltola H, Paakkonen M, Kallio P, Kallio MJT, TO-SASG. Short-versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood. Pediatr Infect Dis J. 2010;29:1123–8.
Peltola H, Paakkonen M, Kallio P, Kallio MJT, The OM-SA Study Group. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood-a prospective quasi-randomized controlled trial. Clin Microbiol Infect. 2012;18:582–9.
Tetzlaff TR, Howard JB, McCraken GH, Calderon E, Larrondo J. Antibiotic concentrations in pus and bone of children with osteomyelitis. J Pediatr. 1978;92:135–40.
Jagodzinski NA, Kanwar R, Graham K, Ed F, Bache CE, Tr F. Prospective evaluation of a shortened regimen of treatment for acute osteomyelitis and septic arthritis in children. J Pediatr Orthop. 2009;29:518–25.
Tetzlaff TR, McCracken GHJ, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr. 1978;92:485–90.
Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48:89–124.
Afghani B, Kong V, Wu FL. What would pediatric infectious disease consultants recommend for management of culture-negative acute osteomyelitis? J Pediatr Orthop. 2007;27:805–9.
Fass RJ. Treatment of osteomyelitis and septic arthritis with cefazolin. Antimicrob Agents Chemother. 1978;13:405–11.
Wieland BW, Marcantoni JR, Bommarito KM, Warren DK, Marschall J. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections Due to Methicillin–Susceptible Staphylococcus aureus. Clin Infect Dis. 2012;54:585–90.
Nguyen HM, Jones RN. Susceptible staphylococcus prosthetic joint infections: using the oxacillin minimum inhibitory concentration to guide appropriate. Clin Infect Dis. 2013;57:161–2.
Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection : clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2013;56:e1–25.
Ambrose PG. Ceftriaxone: reappraisal of Federal Drug Administration in vitro susceptibility testing interpretive criteria: Institute for Clinical Pharmacodynamics 2011. http://www.clsi.org/wp-content/uploads/2011/12/6_MicroAST_PK_PDCeftriaxone_Jan2011.pdf.
Sader HS, Johnson DM, Jones RN. In Vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci. Antimicrob Agents Chemother. 2004;48:53–62.
Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med. 2003;114:723–8.
Guglielmo BJ, Luber AD, Paletta DJ, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis. 2000;30:205–7.
Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PG. Clindamycin treatment of osteomyelitis and septic arthritis in children. Pediatr. 1975;55:213–23.
Saavedra-Lozano J, Mejias A, Ahmad N, Peromingo E, Ardura MI, et al. Changing trends in acute osteomyelitis in children: impact of methicillin-resistant Staphylococcus aureus infections. J Pediatr Orthop. 2008;28:569–75.
Chang F-Y, Peacock JEJ, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Med (Baltim). 2003;82:333–9.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.
Matthews PC, Taylor A, Byren I, Atkins BL. Teicoplanin levels in bone and joint infections: are standard doses subtherapeutic? J Infect. 2007;55:408–13.
Pacifici GM. Clinical pharmacology of teicoplanin in neonates: effects and pharmacokinetics. Int J Pediatr. 2016;4:3669–84.
Dufort G, Ventura C, Olive T, Ortega JJ. Teicoplanin pharmacokinetics in pediatric patients. Pediatr Infect Dis J. 1996;15:494–8.
Garazzino S, Aprato A, Baietto L, D'Avolio A, Maiello A, De Rosa FG, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the Tibia. Clin Pharmacokinet. 2008;47:793–805.
Chiappini E, Serrano E, Galli L, Villani A, Krzysztofiak A. Practical issues in early switching from intravenous to oral antibiotic therapy in children with uncomplicated acute hematogenous osteomyelitis: results from an italian survey. Int J Environ Res Public Health. 2019. https://doi.org/10.3390/ijerph16193557.
Brehin C, Claudet I, Dubois D, Sales de Gauzy J, Vial J, Chaix Y, et al. Assessing the management of pediatric bone and joint infections according to French guidelines. Med Mal Infect. 2019. https://doi.org/10.1016/j.medmal.2019.07.016.
Thakolkaran N, Shetty AK. Acute hematogenous osteomyelitis in children. Ochsner J. 2019;19:116–22.
Schuppen J, van Doorn M, Rijn R. Childhood osteomyelitis: imaging characteristics. Insights. Imaging. 2012;3:519–33.
Batchelder N, So T-Y. Transitioning antimicrobials from intravenous to oral in pediatric acute uncomplicated osteomyelitis. World J Clin Pediatr. 2016;5:244–50.
Chen C-J, Chiu C-H, Lin T-Y, Lee Z-L, Yang W-E, Huang Y-C. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J. 2007;26:985–8.
Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32:66–88.
Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother. 2004;38:338–41.
Kim BN, Kim ES, Oh MD. Oral antibiotic treatment of Staphylococcal bone and joint infections in adults. J Antimicrob Chemother. 2014;69:309–22.
Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim–sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother. 1988;22:873–80.
Saux MC, Le Rebeller A, Leng B, Mintrosse J. Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author’s transl). Pathol Biol (Paris). 1982;30:385–8.
Stein A, Bataille JF, Drancourt M, Curvale G, Argenson JN, Groulier P, et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother. 1998;42:3086–91.
Eliakim-Raz N, Hellerman M, Yahav D, Cohen J, Margalit I, Fisher S, et al. Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study. J Antimicrob Chemother. 2017;72:2687.
Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). Int J Antimicrob Agents. 2018;51:608–11.
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79.
Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS, et al. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). Int J Antimicrob Agents. 2016;47:495–9.
Kiang TKL, Wilby KJ, Ensom MHH. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Clin Pharmacokinet. 2015;54:915–31.
Jacqueline C, Amador G, Caillon J, Le Mabecque V, Batard E, Miègeville AF, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother. 2010;65:1749–52.
Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–6.
Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537–41.
Norden CW, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis. 1983;147:352–7.
Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis. 2013;208:75–82.
Rojo P, Barrios M, Palacios A, Gomez C, Chaves F. Community-associated Staphylococcus aureus infections in children. Expert Rev Anti Infect Ther. 2010;8:541–54.
Funding
This article is not funded by any sources.
Author information
Authors and Affiliations
Contributions
CS, MC, GC, DDL, and DD have made substantial contributions to the conception, design, collection, and interpretation of data for this review, drafted the manuscript, revised it critically for content, and approved the final version.
Corresponding author
Ethics declarations
Ethical approval
Ethical approval was not needed, since this article was a review article.
Conflict of interest
The authors do not have any conflict of interest. No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Congedi, S., Minotti, C., Giaquinto, C. et al. Acute infectious osteomyelitis in children: new treatment strategies for an old enemy. World J Pediatr 16, 446–455 (2020). https://doi.org/10.1007/s12519-020-00359-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-020-00359-z